Skip to main content

Non-Hodgkin Lymphoma

Non-Hodgkin Lymphoma

Criteria to qualify for study: Drug used in study:
  • Roll over study for Hemref34 patients

Hemref 45 Infinity Pharmaceuticals INC Research

A Long-term, Continued Treatment and Follow-up Study in Subjects with Hematologic Malignancies Treate with Duvelisib (IPI-145)

Refractory/ Aggressive

Criteria to qualify for study: Drug used in study:
  • Mantle Cell Lymphoma
  • Pathologically confirmed MCL with documentation of either overexpression of cyclin D1 or presence of t(11;14)
  • Up to 5 prior regimens for MCL and must include Anthracycline or Bendamustine containing chemo and Anti-CD20 monoclonal antibody therapy and Ibrutinib
  • ANC > 1000, Plt > 50 , serum creat < 1.5, bili < 1.5

LYM 111 KTE-C19-102 Kite Pharma

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19in subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

Criteria to qualify for study: Drug used in study:
  • Relapsed/Refractory
  • Phase 1a Escalation
  • Advanced lymphoma after failure of at least 2 prior regimens with at least 1 site of measurable disease (> 1.5 cm in long axis or > 1.0 cm in both long and short axis
  • ANC > 1.5 / PLT > 75 HGB > 10 in absence of transfusion and growth factors for at least 28 days /ECOG 0,1 or 2

Hemref 43 Trillium

A Phase 1a/1b Dose Escalation and Expansion Trial of Single agent TTI-621, a Novel Biologic Targeting CD47, in Subjects with Relapsed of Refractory Hematologic Malignancies